At Viatris, we recognize the responsibility that comes with our role as a leader in this space. We have 90+ antibiotics in our global portfolio and take pride in our contribution to facilitating access to antibiotics.
As a founding member of the AMR Industry Alliance, Viatris is committed to partnering across industry to collectively advance initiatives addressing AMR. These efforts have led to progress in advancing science-based approaches to help manage the impact of anti-microbial manufacturing, develop initiatives to enhance antibiotic stewardship and improve sustainable access to appropriate antibiotics. The AMR Industry Alliance Progress Report showcases the work of Viatris, and other Alliance member companies committed to tackling AMR, together.
In the Access to Medicine Foundation’s AMR Benchmark, Viatris was recognized as one of the top three generics manufacturers for championing appropriate access, stewardship, and responsible manufacturing. We were commended for our transparency in reporting on our environmental risk management strategy for manufacturing sites and for meeting discharge targets at our sites. The report also recognized Viatris’ strategies for expanding access, including making treatment for drug-resistant TB available in more countries than ever and ensuring a continuous supply of relevant products. We were also acknowledged for our AMR education programs for healthcare providers.